We’re excited to announce that today, Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
Foundational Tools for Building a New Bioeconomy
Microfluidic chip-based single-cell cloning to accelerate biologic production timelines
High-throughput optofluidic screening for improved microbial cell factories via real-time micron-scale productivity monitoring
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Assuring Clonality on the Beacon Digital Cell Line Development Platform
Nanoscale Integration of Single Cell Biologics Discovery Processes Using Optofluidic Manipulation and Monitoring
Rapid single B cell antibody discovery using nanopens and structured light
Multiparameter cell characterization using nanofluidic technology facilitates real-time phenotypic and genotypic elucidation of intratumor heterogeneity
A Novel Mammalian Cell Line Development Platform Utilizing Nanofluidics and OptoElectro Positioning Technology
Light-Activated Cell Identification and Sorting (LACIS): A New Method to Identify and Select Edited Clones on a Microfluidic Device
Abveris on important lessons learned through using the Beacon system for antibody discovery.
Thermo Fisher Scientific on developing a faster, more efficient, and regulatory ready cell line and cell culture.
Samsung Biologics on how to expedite development timeline and obtain IND clearance and starting phase 1 study faster.
Thermo Fisher Scientific on how to get more molecules to the clinic faster.
Medical College of Wisconsin on how to determine the phenotypic and functional characteristics of cells in real time, isolate specific cells of interest, and link the genomic profiles of these same cells using downstream assays.
Abveris, Genovac, and Berkeley Lights on the evolving landscape of antibody therapeutics, the technologies they have turned to to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Genovac on how to find 10 times more lead candidates than hybridoma in just days.
Genovac and Berkeley Lights on how to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Nobel Laureate, Dr. James Rothman, Amgen, Catalent-Biologics, and University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Vanderbilt University Medical Center on how to rapidly discover hundres of unique antibodies against SARS-CoV-2.
Children’s Hospital of Philadelphia shares insight into why children’s T cells help CAR-T cells succeed and how to develop more efficacious therapies.
Abveris on how to accelerate the development of next-generation antibody therapeutics.